MS
MTNB icon

Maven Securities’s Matinas BioPharma MTNB Stock Holding History

Maven Securities’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-543
Closed -$30K – 1226
2021
Q1 		$30K Buy
+543
New +$36.4K ﹤0.01% 1125

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Maven Securities's MTNB Position: Q2 2021 in Review

Maven Securities sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 543 shares — an estimated $30K sold.

Maven Securities first reported a position in MTNB in Q1 2021 and held it in 1 quarter. The position peaked at $30K in Q1 2021. 67 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

  • Maven Securities reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 543 Matinas BioPharma shares in Q2 2021, an estimated $30K.
  • Maven Securities first reported a position in Matinas BioPharma in Q1 2021 and held it in 1 quarter.
  • Maven Securities's Matinas BioPharma position peaked at $30K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.